G
17.99
7.39 (69.72%)
| Previous Close | 10.60 |
| Open | 20.00 |
| Volume | 10,291,216 |
| Avg. Volume (3M) | 79,345 |
| Market Cap | 935,985,536 |
| Price / Book | 4.94 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.790 |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 19.60 |
| Operating Cash Flow (TTM) | -37.96 M |
| Levered Free Cash Flow (TTM) | -26.51 M |
| Return on Assets (TTM) | -12.74% |
| Return on Equity (TTM) | -16.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | GH Research PLC | Bullish | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 40.39% |
| % Held by Institutions | 59.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bvf Inc/Il | 30 Sep 2024 | 10,400,158 |
| Lynx1 Capital Management Lp | 30 Sep 2024 | 4,195,894 |
| Verition Fund Management Llc | 30 Sep 2024 | 1,057,782 |
| Cormorant Asset Management, Lp | 30 Sep 2024 | 593,043 |
| 5Am Venture Management, Llc | 30 Sep 2024 | 572,665 |
| Peak6 Investments Llc | 30 Sep 2024 | 74,267 |
| Alps Advisors Inc | 30 Sep 2024 | 38,362 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 122.35%) | Buy |
| Median | 34.00 (88.99%) | |
| Low | 28.00 (Canaccord Genuity, 55.64%) | Buy |
| Average | 34.00 (88.99%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Jan 2025 | 40.00 (122.35%) | Buy | 8.81 |
| 13 Jan 2025 | 40.00 (122.35%) | Buy | 8.35 | |
| Canaccord Genuity | 18 Nov 2024 | 28.00 (55.64%) | Buy | 9.47 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2025 | Announcement | GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction |
| 03 Feb 2025 | Announcement | GH Research Announces Proposed Public Offering |
| 31 Jan 2025 | Announcement | GH Research to Provide Update on Phase 2b Trial with GH001 in TRD |
| 10 Jan 2025 | Announcement | GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents |
| 14 Nov 2024 | Announcement | GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |